Valeant Pharmaceuticals Announces Collaboration Between Bausch + Lomb And IBM
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Valeant (VRX) Derm NRx Up 2.2% Week-over-Week - RBC Capital
May 6, 2016 8:44 AM EDTRBC Capital analyst Douglas Miehm noted Valeant Pharmaceuticals (NYSE: VRX) Derm NRx increased 2.2% WoW, ophth NRx were up 2.7% WoW, and Addyi NRx were down 16.2% WoW.
"For the week ending April 29th, new derm scripts (NRx) were up 2.2% vs. down 2.9% the prior week," Miehm commented. "NRx this week... More
